Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis of new camptothecin analogs with improved antitumor activities.
Niizuma S, Tsukazaki M, Suda H, Murata T, Ohwada J, Ozawa S, Fukuda H, Murasaki C, Kohchi M, Morikami K, Yoshinari K, Endo M, Ura M, Tanimura H, Miyazaki Y, Takasuka T, Kawashima A, Nanba E, Nakano K, Ogawa K, Kobayashi K, Okabe H, Umeda I, Shimma N. Niizuma S, et al. Among authors: tsukazaki m. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21. doi: 10.1016/j.bmcl.2009.02.031. Epub 2009 Feb 12. Bioorg Med Chem Lett. 2009. PMID: 19254843
Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.
Ohwada J, Ozawa S, Kohchi M, Fukuda H, Murasaki C, Suda H, Murata T, Niizuma S, Tsukazaki M, Ori K, Yoshinari K, Itezono Y, Endo M, Ura M, Tanimura H, Miyazaki Y, Kawashima A, Nagao S, Namba E, Ogawa K, Kobayashi K, Okabe H, Umeda I, Shimma N. Ohwada J, et al. Among authors: tsukazaki m. Bioorg Med Chem Lett. 2009 May 15;19(10):2772-6. doi: 10.1016/j.bmcl.2009.03.123. Epub 2009 Mar 28. Bioorg Med Chem Lett. 2009. PMID: 19362835
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Endo M, Miwa M, Ura M, Tanimura H, Taniguchi K, Miyazaki Y, Ohwada J, Tsukazaki M, Niizuma S, Murata T, Ozawa S, Suda H, Ogawa K, Nanba E, Nagao S, Shimma N, Yamada-Okabe H. Endo M, et al. Among authors: tsukazaki m. Cancer Chemother Pharmacol. 2010 Jan;65(2):363-71. doi: 10.1007/s00280-009-1042-5. Cancer Chemother Pharmacol. 2010. PMID: 19495753
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.
Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida M, Kondoh O, Kuramoto S, Ogawa K, Aoki Y, Shimma N. Ohwada J, et al. Among authors: tsukazaki m. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. doi: 10.1016/j.bmcl.2011.01.065. Epub 2011 Jan 22. Bioorg Med Chem Lett. 2011. PMID: 21316229
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.
Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shimma N, Tsukuda T, Ohwada J. Kawada H, et al. Among authors: tsukazaki m. Bioorg Med Chem. 2016 Jul 1;24(13):2897-2906. doi: 10.1016/j.bmc.2016.04.060. Epub 2016 Apr 28. Bioorg Med Chem. 2016. PMID: 27189888
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.
Masubuchi K, Okada T, Kohchi M, Murata T, Tsukazaki M, Kondoh O, Yamazaki T, Satoh Y, Ono Y, Tsukaguchi T, Kobayashi K, Ono N, Inoue T, Horii I, Shimma N. Masubuchi K, et al. Among authors: tsukazaki m. Bioorg Med Chem Lett. 2001 May 21;11(10):1273-6. doi: 10.1016/s0960-894x(01)00178-0. Bioorg Med Chem Lett. 2001. PMID: 11392535
15 results